Akhilesh Sahu, S.K. Azad, Pradeep Kumar Chandrakar, Umesh Dewangan, Vivek Choudhary, Manjula Beck, Rajeev Ratan Jain, Rahul Swaroop Singh and Divya Fransis
Page: 40-44 | Received 20 Feb 2024, Published online: 13 Apr 2024
Full Text Reference XML File PDF File
Objective to assess acute and late toxicities of hypofractionated radiotherapy with concurrent cisplatin for treatment of stage II to IVa head and neck cancer. The present prospective study was conducted in department of Radiotherapy, Pt. JNM medical college and Regional cancer center (RCC) of Dr. BRAM Hospital Raipur. In our study in 6 weeks ‐ skin reaction are‐46.3% cases of grade II and 36.5% cases of grade III. Mucositis are‐ 46.3% cases of grade II and 31.7% cases of grade III. salivary gland toxicity are‐44 % cases of grade II and 31.7% cases of grade III. dysphagia are‐48.7% cases of grade II and 31.7% cases of grade III. Maximum cases have grade 2 followed by grade 3 toxicities. It is due to low immunity in the last week of radiation, absorbed radiation dose is more than tolerance dose of mucosa it is associated with superadded infection we have found that most of the acute toxicities regressed over 3‐4 months at 6th month there is development of late radiation fibrosis and xerostomia.
Akhilesh Sahu, S.K. Azad, Pradeep Kumar Chandrakar, Umesh Dewangan, Vivek Choudhary, Manjula Beck, Rajeev Ratan Jain, Rahul Swaroop Singh and Divya Fransis. Acute and Late Toxicities of Hypofractionated Radiotherapy with Concurrent Cisplatin for Treatment of Stage II to IVA Head and Neck Cancer.
DOI: https://doi.org/10.36478/10.59218/makijtm.2024.2.40.44
URL: https://www.makhillpublications.co/view-article/1816-3319/10.59218/makijtm.2024.2.40.44